Skip to main content
Log in

FK506: therapeutic effects on lupus dermatoses in autoimmune-prone MRL/Mp-lpr/lpr mice

  • Original Paper
  • Published:
Archives of Dermatological Research Aims and scope Submit manuscript

Abstract

The effects of FK506, a new immunosuppressive agent, on the development of lupus dermatoses were investigated in the autoimmune-prone MRL/Mp-lpr/lpr (MRL/lpr) mouse, which is an animal model for the spontaneous development of skin lesions similar to those of human lupus erythematosus (LE). FK506 reduced the incidence of skin lesions, lupus nephritis, the titre of serum anti-double-stranded DNA antibodies and the massive T cell proliferation. The incidence and magnitude of IgG deposition at the dermoepidermal junction were not changed. These results suggest that FK506 is a promising immunosuppressive agent for the control of autoimmune skin diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Abu-Elmagd K, Jegasothy BV, Ackerman CD, Thomson AW, Rilo H, Nikolaidis N, Van Thiel D, Fung JJ, Todo S, Starzl TE (1991) Efficacy of FK506 in the treatment of pyoderma gangrenosum. Transplant Proc 23: 3328–3329

    Google Scholar 

  2. Berden JHM, Faaber P, Assmann KJM, Rijke TPM (1986) Effects of cyclosporin A on autoimmune disease in MRL/l and BXSB mice. Scand J Immunol 24: 405–411

    Google Scholar 

  3. Furukawa F, Tanaka H, Sekita K, Nakamura T, Horiguchi Y, Hamashima Y (1984) Dermatopathological studies on skin lesions of MRL mice. Arch Dermatol Res 276: 186–194

    Google Scholar 

  4. Furukawa F, Imamura S (1986) Pathogenesis of lupus dermatoses in autoimmune mice. VIII. Effects of cyclophosphamide and prednisolone on skin lupus band test and related autoimmune traits in New Zealand mice. Acta Dermatol (Kyoto) 81: 53–58

    Google Scholar 

  5. Furukawa F, Taniguchi S, Tachibana T, Horiguchi Y, Kanauchi H, Ohshio G, Hamashima Y, Imamura S (1988) Pathogenesis of lupus dermatoses in autoimmune mice. X. Evaluation of histamine-N-methyltransferase activity in the skin of autoimmune mice. Microbiol Immunol 32: 83–96

    Google Scholar 

  6. Furukawa F, Ohshio G, Imamura S (1993) Pathogenesis of lupus dermatoses in autoimmune mice. XIX. Attempts to induce subepidermal immunoglobulin deposition in MRL/Mp-+/+ mice. Arch Dermatol Res 285: 20–26

    Google Scholar 

  7. Horiguchi Y, Furukawa F, Hamashima Y, Imamura S (1984) Ultrastructural observations of skin lesions in MRL mice — dermoepidermal junction. Arch Dermatol Res 276: 229–234

    Google Scholar 

  8. Horiguchi Y, Furukawa F, Hamashima Y, Imamura S (1986) Ultrastructural lupus band test in the skin of MRL mice. Arch Dermatol Res 278: 474–480

    Google Scholar 

  9. Horiguchi Y, Furukawa F, Imamura S (1986) Ultrastructural observations of skin lesions in MRL mice — dermal infiltrations and capillary changes. J Dermatol 13: 440–447

    Google Scholar 

  10. Jegasothy BV, Ackerman CD, Todo S, Fung JJ, Abu-Elmagd K, Starzl TE (1992) Tacrolimus (FK506) — a new therapeutic agent for severe recalcitrant psoriasis. Arch Dermatol 128: 781–785

    Google Scholar 

  11. Kanauchi H, Furukawa F, Imamura S (1991) Characterization of cutaneous infiltrates in MRL/lpr mice monitored from onset to the full development of lupus erythematosus-like skin lesions. J Invest Dermatol 96: 478–483

    Google Scholar 

  12. Kanauchi H, Takigawa M, Imamura S, Furukawa F (1994) Effects of cyclosporin A on lupus dermatoses in autoimmune prone MRL/Mp-lpr/lpr mice. J Dermatol Treat 5: 187–191

    Google Scholar 

  13. Kanauchi H, Imamura S, Takigawa M, Furukawa F (1994) Evaluation of the Japanese-Chinese herbal medicine, Kampo for the treatment of lupus dermatoses in autoimmune prone MRL/Mp-lpr/lpr mice. J Dermatol 21: 935–939

    Google Scholar 

  14. Kavai M, Banyai A, Zsindely A, Sonkoly I, Sogedi G (1982) Enzyme-linked immunosorbent assay for antibodies to native DNA in sera of patients with SLE. J Immunol Methods 48: 169–175

    Google Scholar 

  15. Kino T, Hatanaka H, Hashimoto M, Nishiyama M, Goto T, Okuhara M, Kohsaka M, Aoki H, Imanaka H (1987) FK506, a novel immunosuppressant isolated from a streptomyces. 1. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot 40: 1249–1255

    Google Scholar 

  16. Knight JG, Adams DD, Purves HD (1977) The genetic contribution of the NZB mouse to the renal disease of the NZB x NZW hybrid. Clin Exp Immunol 28: 352–358

    Google Scholar 

  17. Meingassner JG, Stutz A (1992) Immunosuppressive macrolides of the type FK506: a novel class of topical agents for treatment of skin diseases? J Invest Dermatol 98: 851–855

    Google Scholar 

  18. Mountz JD, Smith HR, Wilder RL, Reeves JP, Steinberg AD (1987) CsA therapy in MRL-lpr/lpr mice: amelioration of immunopathology despite autoantibody production. J Immunol 138: 157–163

    Google Scholar 

  19. Murphy ED, Roths JB (1978) Autoimmunity and lymphoproliferation. Induction by mutant gene lpr, and acceleration by a male-associated factor in strain BXSB mice. In: Bigazzi PE, Warner NL (ed) Genetic control of autoimmune disease. Elsevier, New York, pp 207–221

    Google Scholar 

  20. Ohshio G, Furukawa F, Yoshioka H, Taki Y, Manabe T, Ozawa K, Tobe T, Hamashima Y (1987) High levels of antimitochondrial antibodies in MRL mice. Influence of anti-DNA antibodies on anti-mitochondrial antibodies measured by an enzyme-linked immunosorbent assay. Microbiol Immunol 31: 75–81

    Google Scholar 

  21. Paulis A, Stellato C, Cirillo R, Ciccarelli A, Oriente A, Marone G (1992) Anti-inflammatory effect of FK506 on human skin mast cells. J Invest Dermatol 99: 723–728

    Google Scholar 

  22. Starzl TE, Todo S, Fung J, Demetris AJ, Venkataramanan R, Jain A (1989) FK506 for liver, kidney and pancreas transplantation. Lancet II: 1000–1004

    Google Scholar 

  23. Tachibana T, Furukawa F, Taniguchi S, Hamashima Y, Imamura S (1985) Histamine metabolism in skin of MRL/l mice. Arch Dermatol Res 278: 57–60

    Google Scholar 

  24. Takabayashi K, Koike T, Kurasawa K, Matsumura R, Sato T, Tomioka H, Ito I, Yoshiki T, Yoshida S (1989) Effect of FK506, a novel immunosuppressive drug on murine systemic lupus eryfhematosus. Clin Immunol Immunopathol 51: 110–117

    Google Scholar 

  25. Takagishi K, Yamamoto N, Nishimura A, Yamasaki G, Kanazawa N, Hotokebuchi T, Kaibara N (1989) Effects of FK506 on collagen arthritis in mice. Transplant Proc 21: 1053–1055

    Google Scholar 

  26. Thomson AW, Starzl TE (1992) FK506 and autoimmune disease: perspective and prospects. Autoimmunity 12: 303–313

    Google Scholar 

  27. Watanabe-Fukunaga R, Brannan CI, Itoh N (1992) The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J Immunol 148: 1274–1279

    Google Scholar 

  28. White DJG (1991) FK506: the promise and the paradox. Clin Exp Immunol 83: 1–3

    Google Scholar 

  29. Yamamoto K, Mori A, Nakahama T, Ito M, Okudaira H, Miyamoto T (1990) Experimental treatment of autoimmune MRL-lpr/lpr mice with immunosuppressive compound FK506. Immunology 69: 222–227

    Google Scholar 

  30. Yamamoto S, Jiang H, Kato R (1994) Stimulation of hair growth by topical application of FK506, a potent immunosuppressive agent. J Invest Dermatol 102: 160–164

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Furukawa, F., Takigawa, M. & Imamura, S. FK506: therapeutic effects on lupus dermatoses in autoimmune-prone MRL/Mp-lpr/lpr mice. Arch Dermatol Res 287, 558–563 (1995). https://doi.org/10.1007/BF00374076

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00374076

Key words

Navigation